Trial Profile
Neointimal coverage with Everolimus-eluting Bioresorbable Scaffolds at the coronary bifurcation lesions using optical coherence tomography (OCT).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Feb 2016
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Pharmacodynamics
- 11 Feb 2016 New trial record